Advertisement

European Journal of Nutrition

, Volume 57, Issue 6, pp 2069–2079 | Cite as

The effect of almonds on vitamin E status and cardiovascular risk factors in Korean adults: a randomized clinical trial

  • Hana Jung
  • C.-Y. Oliver Chen
  • Jeffrey B. Blumberg
  • Ho-Kyung KwakEmail author
Open Access
Original Contribution

Abstract

Purpose

Almonds have shown to beneficially modify some cardiovascular risk factors in clinical trials conducted in diverse ethnic populations but this relationship has never been tested in Koreans. Thus, we tested the impact of almonds consumed as a snack within the context of a typical Korean diet on cardiovascular risk factors.

Methods

We conducted a randomized, crossover trial in a free-living setting with a 2-week run-in period, two 4-week intervention phases, and a 2-week washout period between interventions. Eighty four overweight/obese participants (11 M/73 F; 52.4 ± 0.6 year; 25.4 ± 0.22 kg/m2) consumed either 56 g of almonds or isocaloric cookies daily for 4 weeks.

Results

Mean % daily energy intake at baseline was 64.8, 21.3, and 14.9% from carbohydrate, fat, and protein, respectively. The addition of 56 g of almonds daily decreased carbohydrate energy to 55.0%, increased fat to 32.0%, and maintained protein at 14.7%. Consuming the almonds increased intake of MUFA by 192.3%, PUFA by 84.5%, vitamin E by 102.7%, and dietary fiber by 11.8% and decreased % energy from carbohydrate by 14.1%. Total caloric intake was increased by the almonds, but body weight, waist circumference, and body composition were not affected. Almonds in overweight and obese Korean adults decreased TC, LDL-C, and non-HDL-C by 5.5, 4.6, and 6.4%, respectively, compared to the cookie control (P ≤ 0.05). Almonds increased plasma α-tocopherol by 8.5% (P ≤ 0.05) from the baseline and tended to increase its value as compared to cookies (P = 0.055). Neither the almonds nor cookies altered plasma protein carbonyls, MDA or oxLDL. Of serum inflammatory markers, IL-10 was decreased by almond intake (P ≤ 0.05), and ICAM-1, IL-1β, and IL-6 tended to be lower with almonds, compared to the cookies.

Conclusions

Almonds at 56 g/day consumed as a snack favorably modified the Korean diet by increasing MUFA, PUFA, vitamin E, and dietary fiber intake and decreasing % energy intake from carbohydrate. Almonds also enhanced plasma α-tocopherol status and serum TC and LDL-C in overweight and obese Koreans. Thus, including almonds in typical Korean diets as a snack can help healthy overweight/obese individuals improve nutritional status and reduce their risk for CVD.

Keywords

Almonds Cholesterol α-Tocopherol Cardiovascular risk factor Oxidative stress Inflammation Human 

Abbreviations

Apo A

Apolipoprotein A

Apo B

Apolipoprotein B

BMI

Body mass index

CVD

Cardiovascular disease

HDL-C

High-density lipoprotein cholesterol

hs-CRP

High-sensitive C-reactive protein

ICAM

Intercellular adhesion molecule

IL

Interleukin

KNHANES

Korea National Health and Nutrition Examination Survey

LDL-C

Low-density lipoprotein cholesterol

MDA

Malondialdehyde

MUFA

Monounsaturated fatty acids

oxLDL

Oxidized low-density lipoprotein cholesterol

PUFA

Polyunsaturated fatty acids

SFA

Saturated fatty acids

TC

Total cholesterol

TG

Triglyceride

TNF-α

Tumor necrosis factor-α

VCAM

Vascular cell adhesion molecule

Introduction

Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in the world [1], including in South Korea [2]. Risk factors for CVD are numerous and include dyslipidemia, hypertension, smoking, obesity, sedentary lifestyle, stress, family history of CVD, and insulin resistance [1, 3]. The prevalence of hypercholesterolemia (TC ≥240 mg/dL) among adults ≥30 year in South Korea was 14.6% according to the data of the 2014 Korea National Health and Nutrition Examination Survey (KNHANES) [2], which is comparable to values reported in America (15%, ≥20 year) [4] and China (14.7%, ≥18 year) [5]. Importantly, the prevalence of hypercholesterolemia has been gradually increasing during the last decade in South Korea [2]. Overweight/obesity and diet are two principal modifiable factors affecting the development of hypercholesterolemia [6]. In South Korea, the incidence of obesity among adults (BMI ≥25, based on the WHO obesity guideline for the Asia–Pacific region) [7] is 37.7% in men and 25.3% in women [2]. To reduce the risk of CVD, approaches to mitigating modifiable risk factors, such as unhealthy diets and sedentary lifestyles, are recommended to be undertaken by all people, especially those at increased risk associated with unmodifiable factors such as age and genetics.

The traditional Korean diet is rich in carbohydrates and low in fats, with carbohydrate (CHO), fat, and protein contributing to 72.1, 13.4, and 14.5%, respectively, of total energy intake [8]. Further, in the KNHANES data [2], the contribution of CHO to total energy intake is 63.8%, which is even higher in adults ≥50 year. In the typical Korean diet, grains and grain-based foods contribute about 48%, and white rice contributes about 25% of energy [2]. This rice-based dietary pattern predisposes Koreans to obesity, dyslipidemia and diabetes [9]. Besides being a CHO-predominate dietary pattern, the typical Korean diet is inadequate in some micronutrients. For example, 70% of Korean adults do not consume the estimated average requirement for calcium recommended by the Dietary Reference Intakes for Koreans (KDRI) [2]. Korean adults consume over 50% of vitamin E in γ-tocopherol form and only 22% in α-tocopherol form [10]. Furthermore, 23% of Korean adults have plasma α-tocopherol concentration lower than 12 μmol/L, a threshold level of vitamin E deficiency, and 90% of Korean adults have its level below 20 μmol/L [10], which is associated with increased CVD risk [11, 12]. Both α- and γ-tocopherol have been reported to exert anti-inflammatory actions [11]. Thus, incorporating foods high in quality fats and micronutrients into the Korean diet would be expected to improve overall nutrition status.

Nuts, including tree nuts and peanuts, contain a wide range of beneficial nutrients, such as fiber, protein, unsaturated fats, vitamins, minerals, and phytosterols and other phytochemicals [13, 14]. Of all tree nuts, almonds have been frequently demonstrated in clinical studies to lower blood glucose and cholesterol and attenuate biomarkers of inflammation and oxidative stress, all are risk factors of CVD [15, 16, 17, 18, 19, 20, 21]. These benefits are mainly ascribed to their nutrient composition being low in saturated fatty acids (SFA) and rich in unsaturated fatty acids (91–94% fats are oleic acid and linoleic acid) and α-tocopherol and containing fiber, phytosterols, and proteins [20]. Thus, incorporating almonds into typical Korean diets might be expected to support cardiovascular health and improve the status of certain nutrients, such as vitamin E.

The benefit to cardiovascular health of almond consumption has been demonstrated in people living in Canada, China, Taiwan, United States, and United Kingdom, but not in South Korea. However, the health benefit of any specific food is subject to the influence of many physiological, genetic, dietary, and environmental factors. As ethnicity and background diet may modulate the bioefficacy of almond nutrients, we tested the impact of almonds on CVD risk factors in overweight/obese Korean adults. We hypothesized that almonds could improve vitamin E status and CVD risk factors including lipid profile, oxidative stress, and inflammation.

Subjects and methods

Subjects

Subjects were recruited in the Seoul metropolitan area by advertising on the website of Korea National Open University and the campus bulletin boards (Fig. 1). The eligibility criteria included: (1) men and women aged 45–69 year, (2) BMI 23–29.9 kg/m2 or waist circumference ≥85 cm for women, ≥90 cm for men, (3) free of any diagnosed chronic disorders or acute inflammatory diseases 2 year prior to the enrollment, (4) no known allergies to nuts, (5) nonsmoking (or ceased smoking for ≥1 year), (6) not taking any vitamin supplements, functional foods or hormone replacement therapy for the last 1 month prior to the enrollment, (7) not taking any medications known to affect lipid metabolism, such as statins, (8) consuming typical Korean diet. Subjects who had passed an initial phone screening were invited for on-site screening to confirm their eligibility. The study was approved by the Institute Review Board of the Korea National Open University, and informed consent was obtained from each participant before the conduct of any study element was performed. The trial was registered in the Institute Review Board of the Korea National Open University: KNOU IACF (ABN01-201412-11-28).
Fig. 1

CONSORT of flow chart of study

Experimental design

The study was a 12-week randomized crossover intervention trial in a free-living setting (Fig. 2). During the study, subjects were asked to consume their habitual diet without nuts. After 2 weeks of run-in period, eligible subjects were randomly assigned to one of two sequences [almond then control (AC) and control then almond (CA)] by asking them to draw a card (blue card: AC; orange card: CA). Subjects were then instructed to consume either 56 g/day of roasted almonds or 70 g/day of isocaloric home-made cookies as a snack for 4 weeks in the first intervention phase. After the 2-week washout period, subjects consumed the alternate food for another 4 weeks in the second phase. The daily dose of almonds and cookies was individually packaged. Almonds or cookies were provided to subjects every 2 weeks. Subject compliance was assessed with a diary calendar and counting returned packages. Four 3-day dietary records (2 weekdays and 1 weekend day) were collected in the final week of the run-in, washout, and intervention phases. Nutrient intakes were assessed using a computer aided nutritional analysis program for professionals (CAN pro 4.0, The Korean Nutrition Society).
Fig. 2

Study design

Study foods

Roasted almonds were generously provided by the Almond Board of California. The cookies were made with white flour, butter, sugar, egg, baking powder, and salt in a local bakery. After preparation, the cookies were stored in sealed aluminum foil zipper bag pouches, at room temperature, protected from light and air. The nutrient composition of almonds and cookies is presented in Table 1.
Table 1

Nutrient composition of almonds and cookies

Nutrients

Cookies

per 70 g

Roasted almonds

per 56 g

Calories

kcal

340

340

Moisture

g

1.5

1.4

Protein (% kcal)

g

4 (4.7)

12 (14.1)

CHO (% kcal)

g

47.3 (55.6)

5.5 (6.5)

Total sugar (% kcal)

g

16.0 (18.8)

2.8 (3.3)

Total fat (% kcal)

g

15 (39.7)

30 (79.4)

SFA (% kcal)

g

8.4 (22.2)

2.3 (6.1)

MUFA (% kcal)

g

3.2 (8.5)

19 (50.3)

PUFA (% kcal)

g

0.6 (1.6)

7.3 (19.3)

Total dietary fiber

g

0.7

6.2

Calcium

mg

14

150

Iron

mg

0.4

2.1

Magnesium

mg

9

160

Phosphorus

mg

67

270

Potassium

mg

58

400

Sodium

mg

152

2

Zinc

mg

0.4

1.9

α-tocopherol

mg

0.41

14.0

CHO carbohydrate, SFA saturated fatty acids, MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids

Anthropometric analyses

Body weight, height, body composition, and blood pressure were measured before and after each intervention phase. Body weight and height were measured using an anthropometer (HC-1000, Cas Korea, Seoul, Korea). BMI was calculated using the weight/height2 (kg/m2) formula. Waist and hip circumferences were measured using a measuring tape. Body composition was assessed using bioelectrical impedance analysis (InBody720, Bio-space, Seoul, Korea). After ≥10 min of rest, blood pressure was determined using an automatic blood pressure monitor (TM-2655P, Bio-space).

Blood collection

After a 12-h fast, venous blood was collected from the brachial vein of one arm before and after each intervention phase. Whole blood was centrifuged at 1500×g for 10 min at 4 °C. Plasma and serum were separated and aliquots were stored in −80 °C until biochemical analyses were performed.

Biochemical analyses

Serum triglyceride (TG), total choesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein choesterol (HDL-C), glucose, high-sensitive C-reactive protein (hs-CRP), apolipoprotein A (apo A), and apolipoprotein B (apo B) were analyzed using an automated biochemical analyzer (Selectra E, Vital Scientific N.V., Dieren, The Netherlands). The intra- and inter-day coefficients of variation (CV) were 1.9 and 5.3% for TG, 0.5 and 8.4% for TC, 3.1 and 4.4% for LDL-C, 3.8 and 7.5% for HDL-C, 1.3 and 9.6% for glucose, 7.7 and 8.4% for hs-CRP, 1.6 and 12.6% for apo A, and 8.8 and 5.4% for apo B, respectively. Plasma protein carbonyls and oxidized low-density lipoprotein cholesterol (oxLDL) were measured using commercial kits (Cell Biolab, San Diego, CA, USA) and a microplate reader (Fluostar Optima, BMG Labtech, Durham, NC, USA). The intra- and inter-day CV for protein carbonyls were 6.8 and 12.2% and for oxLDL were 2.3 and 9.8%, respectively. Tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and IL-10 in serum were determined using a cytometric cytokine bead array human enhanced sensitivity master buffer kit (BD Biosciences, San Jose, CA, USA) and an Accuri C6 flow cytometer (BD Biosciences). Soluble vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) were measured using commercial kits (R&D Systems, Abingdon, UK). The intra- and inter-day CV for VCAM-1 were 1.3 and 12.8% and for ICAM-1 were 5.2 and 11.0%, respectively. Plasma α- and γ-tocopherol were determined using a high-performance liquid chromatography (HPLC) with photo-diode array (PDA) method according to Liu et al. [22]. The intra- and inter-day CV for α-tocopherol were 1.8 and 4.4% and for γ-tocopherol were 1.5 and 5.2%, respectively. Plasma malondialdehyde (MDA) was determined by a reverse-phase HPLC method with the thiobarbituric acid–MDA conjugate being injected onto a C18 column and then quantified with fluorescence detection (Ex515/Em553 nm) according to Volpi and Tarugi [23]. The intra- and inter-day CV for MDA were 3.3 and 7.3%, respectively.

Statistical analyses

The results are expressed as mean ± standard deviation (SD). The data were analyzed using SAS 9.4 for Windows (SAS Institute Inc, Cary, NC). Student’s t test was performed to compare nutrient intakes between the time points. Student’s t test was also used to assess the significance of differences in biochemical biomarkers between cookie baseline and almond baseline, as well as between before and after each intervention phase. The mixed model was performed (SAS: Proc Mixed) to assess the treatment effect to control variance in the outcome by accounting for the crossover nature of the study. In this model, subject was designated as the random effect and treatment and sequence were designated as the fixed effects. Significance was considered at P ≤ 0.05.

Results

Subject characteristics

One hundred forty five people were phone screened, and 99 of them were invited to on-site screening to assess eligibility. Ninety eligible participants were enrolled, and 84 [11 M and 73 W, aged 45–62 year (52.4 ± 0.6 year)] completed the study with full compliance (Fig. 1). Five participants (5 F/1 M) dropped out from the trial due to time commitment (n = 3) and abdominal discomfort caused by almonds in the first week (n = 2). In addition, the data from one participant were not included in data analysis because of the elevated inflammatory status (hs-CPR and IL-6) that was three times of the SD. The percent of overweight (23≤ BMI <25) and obese (BMI ≥25) subjects was 39.3 and 51.2%, respectively (WHO obesity guideline for Asia–Pacific region) [7], and central adiposity (men, waist circumference ≥90, women, waist circumference ≥85) [7]  was 96.4%. The proportion of participants with normal levels of TG [≤1.7 mmol/L (≤150 mg/dL)], TC [≤5.2 mmol/L (≤200 mg/dL)] and LDL-C [≤3.4 mmol/L (≤130 mg/dL)] was 91.7, 57.1, and 57.1%, respectively, and 76.2% of the participants had normal HDL-C [>1.0 mmol/L (>40 mg/dL)] [3]. Most participants (97.6%) had a normal fasting glucose value [≤5.6 mmol/L (≤100 mg/dL)]. Plasma α-tocopherol ranged from 20.7 to 50.0 μmol/L. The proportion of participants with intermediate risk and high risk levels of hs-CRP (>1.0, AHA/CDC guideline) [24] was 19.0%.

Dietary intake

Compared with the values from the pre-almond phase (wk 0), almonds increased total energy by 12.3%, MUFA by 192.3%, PUFA by 84.5%, dietary fiber by 11.8%, vitamin E by 102.7%, calcium by 19.7%, and magnesium by 190.8% and decreased % energy from CHO by 14.1% (Table 2). As compared to the week 4 value of the cookie phase, mean % daily energy intake from CHO was 5.7% lower during the almond phase (P ≤ 0.001), as well as 5.8% higher from fats (P ≤ 0.001). The addition of almonds also significantly increased the intake of PUFA and MUFA, dietary fiber, and vitamin E by 67.9, 107.8, 22.5, and 114.4%, respectively, as compared to the cookie control. Intake of energy, calcium, and magnesium were significantly increased by 6.2, 20.6, and 185.0%, and SFA and cholesterol were significantly decreased by 44.0 and 14.1% during the almond phase compared to the cookie phase.
Table 2

Dietary intake data of the subjects before and after each phasea

 

Cookie

Almond

P valueb

Week 0

Week 4

Week 0

Week 4

Energy (kcal)

1678.1 ± 374.3

1803.3 ± 332.3

1704.3 ± 343.4

1914.4 ± 340.6

0.0224

Carbohydrate (g)

(% of energy)

264.3 ± 62.9

(63.1 ± 6.4)

275.3 ± 60.2

(60.7 ± 5.9)

273.1 ± 4.18

(64.0 ± 7.0)

264.4 ± 58.5

(55.0 ± 6.1)

≤0.001c

Protein (g)

(% of energy)

63.6 ± 16.3

(15.2 ± 2.4)

61.1 ± 14.0

(13.5 ± 1.9)

63.7 ± 15.0

(14.9 ± 2.2)

70.5 ± 15.9

(14.7 ± 2.3)

≤0.001c

Fat (g)

(% of energy)

42.4 ± 14.8

(22.5 ± 5.2)

52.4 ± 11.4

(26.2 ± 4.3)

42.1 ± 5.0

(22.0 ± 4.5)

67.9 ± 14.0

(32.0 ± 4.5)

≤0.001c

SFA (g)

(% of energy)

6.3 ± 4.0

(3.4 ± 2.1)

16.1 ± 4.5

(8.2 ± 2.3)

7.1 ± 4.2

(3.8 ± 2.2)

9.0 ± 3.8

(4.3 ± 1.8)

≤0.001

MUFA (g)

(% of energy)

7.9 ± 4.6

(4.2 ± 2.4)

12.8 ± 5.1

(6.5 ± 2.5)

9.1 ± 5.0

(4.8 ± 2.7)

26.6 ± 5.4

(12.8 ± 2.8)

≤0.001

PUFA (g)

(% of energy)

6.7 ± 3.2

(3.5 ± 1.4)

7.8 ± 2.9

(3.9 ± 1.4)

7.1 ± 2.8

(3.8 ± 1.3)

13.1 ± 3.1

(6.3 ± 1.5)

≤0.001

Cholesterol (mg)

316.7 ± 163.6

345.8 ± 131.6

292.6 ± 158.6

297.2 ± 146.5

0.0413

Fiber (g)

21.0 ± 5.0

20.9 ± 6.0

22.9 ± 6.1

25.6 ± 4.4

≤0.001

Vitamin E (mg)

14.1 ± 5.0

13.9 ± 4.0

14.7 ± 4.4

29.8 ± 4.6

≤0.001

Calcium (mg)

478.8 ± 139.9

500.8 ± 164.5

504.6 ± 178.9

603.9 ± 174.6

≤0.001

Magnesium (mg)

66.5 ± 31.6

74.7 ± 25.4

73.2 ± 28.8

212.9 ± 37.0

≤0.001

Data are expressed as mean ± SD. Nutrient intakes were evaluated using a computer aided nutritional analysis program for professionals (CAN pro 4.0, The Korean Nutrition Society)

SFA Saturated fatty acids, MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids

aDietary record was collected before each phase (week 0) and during the final week of each phase (week 4)

bComparison of values at the end of almond and cookie phases, tested using the mixed model

P ≤ 0.05 and P ≤ 0.001, comparison between almond (week 4) vs. cookie (week 4), tested using Student’s t-test

Anthropometric indices and blood pressure

At the end of the intervention, neither almonds nor cookies altered body weight, waist circumference, body composition, and blood pressure as compared to the respective baseline value (Supplemental Table 1). The overall mean body weight, waist circumference, body fat, and systolic and diastolic blood pressures were 66.2 ± 8.7, 89.5 ± 5.9, 43.1 ± 8.6, 122.1 ± 16.1, and 79.4 ± 10.2, respectively.

Lipid profiles and fasting glucose

Mean TG and HDL-C values were not significantly changed during the intervention (Table 3). However, when compared to the corresponding pre-intervention value, almonds tended to reduce TG by 8.0% (P = 0.189) while the cookies had no impact. As compared to the end value of the cookie phase, almonds decreased TC, LDL-C, and non-HDL-C by 5.5, 4.6 and 6.4%, respectively (P ≤ 0.05), and tended to decrease serum apo B by 4.6% (P = 0.109). Neither almonds nor cookies affected blood glucose status.
Table 3

Lipid profiles and fasting glucose of the subjects before and after each phase

 

Cookie

Almond

P valuea

Week 0

Week 4

Week 0

Week 4

TG (mmol/L)

1.09 ± 0.48

1.08 ± 0.50

1.12 ± 0.49

1.03 ± 0.46

0.1583

TC (mmol/L)

5.08 ± 0.93

5.28 ± 1.01

4.99 ± 0.88

4.99 ± 0.91

0.0198

LDL-C (mmol/L)

3.29 ± 0.70

3.41 ± 0.78

3.23 ± 0.68

3.19 ± 0.70

0.0222

HDL-C (mmol/L)

1.24 ± 0.28

1.28 ± 0.25

1.21 ± 0.26

1.26 ± 0.30

0.9573

Apo A (mg/dL)

150.59 ± 24.71

157.33 ± 25.84

150.62 ± 25.84

153.95 ± 25.97

0.1319

Apo B (mg/dL)

91.09 ± 19.10

92.31 ± 20.70

89.34 ± 19.02

87.98 ± 18.83

0.1091

Apo B/Apo A

0.62 ± 0.16

0.60 ± 0.16

0.61 ± 0.15

0.58 ± 0.14

0.6557

LDL-C/HDL-C

2.81 ± 0.91

2.76 ± 0.78

2.79 ± 0.81

2.67 ± 0.80

0.2310

TC/HDL-C

4.31 ± 1.26

4.26 ± 1.03

4.29 ± 1.09

4.15 ± 1.09

0.3578

Non-HDL-Cb

(mmol/L)

3.85 ± 0.92

3.99 ± 0.96

3.78 ± 0.85

3.74 ± 0.88

0.0121

Glucose (mmol/L)

4.80 ± 0.51

4.83 ± 0.68

4.82 ± 0.57

4.76 ± 0.55

0.1125

Data are expressed as mean ± SD

TG triglyceride, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, Apo A apolipoprotein A, Apo B apolipoprotein B

aComparison of values at the end of almond and cookie phases, tested using the mixed model

bNon-HDL-C: total cholesterol-high-density lipoprotein cholesterol

Plasma tocopherol profiles

After 4 weeks of almond consumption, plasma α-tocopherol concentration tended to be higher (P = 0.055) and γ-tocopherol was lower (P ≤ 0.001) than cookie consumption (Fig. 3). When compared with the respective pre-intervention value, almonds increased α-tocopherol concentration by 8.5% (P ≤ 0.05) and decreased γ-tocopherol by 18.1% (P ≤ 0.01). At the end of the intervention, almonds increased the ratio of α-tocopherol to TC by 10.4% (P ≤ 0.001) and decreased the ratio of γ-tocopherol to TC by 20.0% (P ≤ 0.001), as compared to cookies. Compared with the pre-intervention value, almonds increased the ratio of α-tocopherol to TC by 8.0% (P ≤ 0.05) and decreased the ratio of γ-tocopherol to TC by 17.2% (P ≤ 0.01).
Fig. 3

Changes in α- (a) and γ-tocopherol (b) and the ratio of tocopherol to total cholesterol (c, d) in subjects consuming either almonds or cookies for 4 weeks. Data are expressed as mean ± SD. P ≤ 0.05 and P ≤ 0.01, means within each treatment differ between pre- and post-intervention values, tested by Student’s t test. *P ≤ 0.001, post-intervention means differ between almonds and cookies, tested using the mixed model

Biomarkers of oxidative stress and inflammation

Neither almonds nor cookies affected the selected biomarkers of oxidative stress, i.e., plasma protein carbonyls, MDA, and serum oxLDL (Table 4). Almonds did modulate some biomarkers of inflammation as compared to cookies. Almonds decreased post-intervention serum IL-10 concentration by 22.2%, as compared to cookies (P ≤ 0.05). Serum ICAM-1 (P = 0.187), IL-1β (P = 0.137) and IL-6 (P = 0.142) tended to be lowered at the end of the almond phase than the cookie phase. Other biomarkers of inflammation, serum VCAM-1, TNF-α, and hs-CRP, showed no notable changes during the intervention.
Table 4

Biomarkers of oxidative stress and inflammation of the subjects before and after each phase

 

Cookie

Almond

P valuea

Week 0

Week 4

Week 0

Week 4

Oxidative stress markers

 Protein carbonyl (mmol/mL)

0.65 ± 0.41

0.69 ± 0.41

0.68 ± 0.38

0.68 ± 0.37

0.2765

 Malondialdehyde (μmol/L)

1.93 ± 0.38

1.93 ± 0.40

1.94 ± 0.37

1.93 ± 0.40

0.8436

 Oxidized LDL (mg/mL)

6.39 ± 3.76

5.79 ± 4.28

5.71 ± 3.67

5.00 ± 3.40

0.3330

Inflammatory markers

 ICAM-1 (ng/mL)

162.54 ± 66.01

156.30 ± 61.98

169.39 ± 67.53

156.81 ± 61.33

0.1872

 VCAM-1 (ng/mL)

486.19 ± 140.53

472.94 ± 132.69

492.05 ± 142.58

474.11 ± 133.17

0.7731

 IL-10 (pg/mL)

0.23 ± 0.16

0.26 ± 0.24

0.25 ± 0.27

0.20 ± 0.16

0.0393

 IL-1β (pg/mL)

0.07 ± 0.08

0.07 ± 0.08

0.07 ± 0.07

0.06 ± 0.07

0.1372

 IL-6 (pg/mL)

0.70 ± 0.70

0.66 ± 0.63

0.70 ± 0.67

0.57 ± 0.58

0.1419

 TNF-α (pg/mL)

0.10 ± 0.09

0.10 ± 0.78

0.11 ± 0.09

0.10 ± 0.09

0.9514

 hs-CRP (mg/dL)

0.11 ± 0.31

0.11 ± 0.21

0.11 ± 0.21

0.08 ± 0.11

0.3205

Data are expressed as mean ± SD

ICAM intercellular adhesion molecule, VCAM vascular cell adhesion molecule, IL interleukin, TNF-α tumor necrosis factor-α, hs-CRP high-sensitive C-reactive protein

aComparison of values at the end of almond and cookie phases, tested using the mixed model

Discussion

Several studies support a cardiometabolic benefit of almond consumption based on their association with improvements to lipid profile, blood glucose, inflammation, and oxidative stress [15, 16, 17, 18, 19]. However, such benefits are always subject to the influence of other factors, including background diet and ethnicity. As the impact of almonds has not been examined in Koreans, this study tested whether almonds consumed as a snack could improve vitamin E status, lipid profile, and biomarkers of oxidative stress and inflammation in overweight/obese Korean adults.

Almonds are a nutrient dense food because they are a particularly good source of unsaturated fatty acids, α-tocopherol, arginine, magnesium, copper, calcium, and potassium [20]. The addition of almonds to a daily diet may improve the nutritional quality of diverse populations by increasing the intake of unsaturated fatty acids, fiber, magnesium, and α-tocopherol [25, 26, 27]. We found that almonds at 56 g/day improved the nutrition quality of free-living Koreans consuming a typical national diet. The change in energy distribution from CHO to fat during the almond phase shifted the dietary pattern to one more consistent with the National Cholesterol Education Program (NCEP) guidelines for healthy American adults, i.e., 50–60% calories from CHO, 15% from protein, and 25–35% from fat (≤7% of calories from SFA, up to 10% from PUFA, and up to 20% from MUFA) [28]. Even though the percent of energy from CHO during the almond phase remained within the recommended range for Koreans (55 ~ 65%) [29], we found almonds consumed as a snack enabled a larger change in the contribution of CHO and fat to total energy as compared to the studies with participants consuming Western diets [25, 26]. Almonds increased the intake of vitamin E, fiber, MUFA, and PUFA. Particularly, they doubled vitamin E intake from 14.7 to 29.8 mg/day and elevated fiber intake up to the level (≥25 g/day) recommended in the Korean Guidelines for the Management of Dyslipidemia [3]. Furthermore, almonds enhanced calcium and magnesium intakes closer to the recommended levels for Korean adults ≥45 year (700 ~ 800 mg for calcium and 280 ~ 370 mg for magnesium) [29].

The addition of almonds (56 g/day) as a snack increased mean daily energy intake by 12%, but did not alter body weight. Despite the provision of 15 g fat and 169 kcal energy from a 28 g of serving, several clinical trials reveal that almonds show a beneficial or null effect on body weight [26, 30, 31, 32, 33], likely due to a combination of food displacement and incomplete calorie absorption. For example, Novotny et al. [34] reported that 32% of calories in almonds was not absorbed and excreted in stool as compared the total calories calculated using the Atwater factors.

Korean adults consume 17.7 mg of α-tocopherol equivalents (TE)/day which is larger than the adequate intake level of the KDRI at 12 mg TE/d [10]. However, the intake is actually inadequate because α-tocopherol only accounts for 22% of total vitamin E intake, while γ-, ɗ-, β-tocopherol accounts for 51.7, 12.6, 1.0%, respectively [10]. Almonds are an excellent source of α-tocopherol providing 7.4 mg per 28 g serving [20]. When almonds were consumed as part of Western diets, α-tocopherol intake was increased by 54–98% [18, 35]. Jambazian et al. [36] calculated that every 1% energy increase from almonds (~2.8 g) increases α-tocopherol status by 0.15 μmol/L. In our previous study, we found that 85 g/day of almonds added to the NCEP step 1 diet increased plasma α-tocopherol by 5.8% in patients with coronary heart disease [26]. The bioavailability of α-tocopherol is affected by habitual diets because of the requirement of fats to facilitate its bioavailability. We found that 56 g/day of almonds increased plasma α-tocopherol by 8.5% and decreased γ-tocopherol by 18.1%, magnitudes of the change consistent with the results of studies conducted in Americans and Chinese [15, 36]. Since 23% of Korean adults are vitamin E deficient based on the plasma α-tocopherol concentration [10], our results support the notion that almonds can be an effective food to prevent vitamin E deficiency and inadequacy in Koreans. The improvement in α-tocopherol status after almond consumption appears more marked when expressed the ratio α-tocopherol:TC, a more accurate values as tocopherols are transported via lipoproteins and their circulating concentrations are associated with TC [36].

A recent meta-analysis of 18 randomized controlled trials showed that almonds improved TC, LDL-C, and TG statuses but had no effect on HDL-C [21]. The favorable effects of almonds on serum lipid profiles proceed in a dose-responsive manner, particularly among individuals with hyperlipidemia [37, 38, 39], with a 1% reduction in LDL-C associated with each 7 g of intake [33, 39, 40]. The hypocholesterolemic effect of almonds appears to extend to patients taking statins [41]. Similarly, Lee et al. [42] found that daily consumption of 30 g of mixed nuts for 6 weeks decreased TC by 4% in Korean women with metabolic syndrome. Further, the addition of nuts to Korean diets may help control the lipid profile among those at increased risk for non-alcoholic fatty liver disease [43]. Consistent with these data, we found that almonds consumed as a snack were beneficial to lipid profile in Koreans as compared to cookies. Korean Guidelines for the Management of Dyslipidemia suggest nuts as an appropriate fat source [3]. In addition, the guidelines recommend limited intakes of biscuit, cookie, and cake, which rank 13th~14th of the main sources of fat intake in Korean diet [2]. These confectionary foods are major processed food sources of total sugar intake in Koreans [44, 45]; however, frequent consumption of sweet snacks is not consistent with dietary patterns for heart health [8, 9]. In contrast, the nutritional profile and impact on lipid profiles suggest almonds as a better snack. Nevertheless, among the main sources of fat in Korean diet, almonds rank 26th with the estimated average almond intake 0.65 g/day, which provide 0.35 g/day of fat and contribute 0.15% daily energy intake [2]. Together with well consistent data on lipid profile in the literature, our study suggests that almonds shall be incorporated into Korean diet for heart health as Koreans consume approximately 0.65 g/day, which is much lower than the intake (1.5 oz or 42.5 g/day) recommended in the FDA qualified health claim for tree nuts [46].

The effects of almonds on oxidative stress and inflammation reported in the literature are mixed, likely due to variations in study design, subject inclusion criteria, etc. Jenkins et al. [33] found that 73 g/day of almonds decreased serum MDA of older subjects with dyslipidemia. However, Choudhury et al. [47] reported that 50 g/day of almonds did not affect plasma protein carbonyl or nitric oxide in adults with ≥2 CVD risk factors. The data in this study did not reveal any modification of three common biomarkers of oxidative stress, plasma protein carbonyls, MDA, and oxLDL. Similarly, Lee et al. [42] also obtained null results on biomarkers of oxidative stress in a study of mixed nuts in Koreans with metabolic syndrome. However, it is worthwhile noting that nuts, specifically almonds, peanuts and pine nuts are included in measures of dietary quality among Koreans which are inversely associated with measures of systemic lipid peroxidation [48].

With regard to biomarkers of inflammation, Rajaram et al. [49] reported that 68 g/day of almonds decreased serum hs-CRP and E-selectin, but did not affect serum IL-6 and fibrinogen. Liu et al. [17] found that almonds incorporated into an NCEP step 2 diet at 20% daily calories decreased IL-6 compared to controls, but did not alter ICAM-1 or VCAM-1 in Chinese patients with type 2 diabetes mellitus. We found the almond snack decreased IL-10 and tended to decrease serum ICAM-1, IL-1β and IL-6. Interestingly, a positive association between IL-10 and CVD risk has been reported among the elderly [50]. The absence of a statistically significant impact of almonds on the biomarkers of inflammation examined in this study may be due to their low concentrations at baseline which matched those of healthy, normal weight people [51, 52]. Nonetheless, a study of mixed nuts in Koreans with metabolic syndrome also found no effect on ICAM-1, VCAM-1, IL-6 or hs-CRP [42].

Daily supplementation of almonds in typical Korean diet for 4 weeks improves nutrient intakes, circulating vitamin E status, and lipid profiles in overweight and obese Koreans. However, there are several limitations in our study. Due to a relatively short intervention duration, the positive effects of chronic almond consumption on the outcome measures remain to be examined. Nutrient intake may not be accurately captured as values were calculated from self-reported dietary information. The sample size of this study may not be powered to detect the effect of almonds on TG, apo B, ICAM-1, IL-1β, and IL-6.

The impact of any food or nutrient on CVD risk must be evaluated against the background of ethnicity, genetics, diet, and lifestyle for the cohort studied. However, our almond intervention in a Korean population appears generally consistent with those found in other Asian as well as North American and European countries. This relationship may result from the positive nutrient attributes of almonds, i.e., their content of MUFA, PUFA, fiber, and vitamin E, and their combined association with heart health.

Notes

Acknowledgements

The study was funded by the Almond Board of California. The contributions of Drs. Chen and Blumberg to the study were partially supported by the US Department of Agriculture (USDA)/Agricultural Research Service under the Cooperative Agreement No. 1950-51000-087. The contents of this publication do not necessarily reflect the views or policies of the USDA nor does mention of trade names, commercial products or organizations imply endorsement by the US government. We are very grateful to the volunteers for their participation in the trial.

Supplementary material

394_2017_1480_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 12 kb)

References

  1. 1.
    Assmann G, Carmena R, Cullen P, Fruchart J-C, Jossa F, Lewis B, Mancini M, Paoletti R, Disease ITFftPoCH (1999) Coronary heart disease: reducing the risk a worldwide view. Circulation 100(18):1930–1938CrossRefPubMedGoogle Scholar
  2. 2.
    Ministry of Health and Welfare of Korea, Korea Centers for Disease Control and Prevention (2014) Korea Health Statistics. Sejong: Ministry of Health and Welfare of KoreaGoogle Scholar
  3. 3.
    Committee for the Korean guidelines for the management of dyslipidemia (2016) 2015 Korean guidelines for the management of dyslipidemia. Circ J 46(3):275–306Google Scholar
  4. 4.
    Jellinger P, Smith D, Mehta A, Ganda O, Handelsman Y, Rodbard H, Shepherd M, Seibel J (2012) American Association of Clinical Endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endoc Pract 18(1):1–78CrossRefGoogle Scholar
  5. 5.
    Qi L, Ding X, Tang W, Li Q, Mao D, Wang Y (2015) Prevalence and risk factors associated with dyslipidemia in Chongqing, China. Int J Environ Res Public Health 12(10):13455–13465CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Quyyumi AA (1998) Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 105(1):32S–39SCrossRefPubMedGoogle Scholar
  7. 7.
    Bassett J, Organization WH (2000) The Asia-Pacific perspective: redefining obesity and its treatment. Health Communications Australia, SydneyGoogle Scholar
  8. 8.
    Song Y, Joung H (2012) A traditional Korean dietary pattern and metabolic syndrome abnormalities. Nutr, Metab Cardiovasc Dis 22(5):456–462CrossRefGoogle Scholar
  9. 9.
    Kim J, Jo I, Joung H (2012) A rice-based traditional dietary pattern is associated with obesity in Korean adults. J Acad Nutr Diet 112(2):246–253CrossRefPubMedGoogle Scholar
  10. 10.
    Kim YN, Cho YO (2015) Vitamin E status of 20- to 59-year-old adults living in the Seoul metropolitan area of South Korea. Nutr Res Pract 9(2):192–198CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Reiter E, Jiang Q, Christen S (2007) Anti-inflammatory properties of α-and γ-tocopherol. Mol Aspects Med 28(5): 668–691CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Singh RB, Ghosh S, Niaz MA, Singh R, Beegum R, Chibo H, Shoumin Z, Postiglione A (1995) Dietary intake, plasma levels of antioxidant vitamins, and oxidative stress in relation to coronary artery disease in elderly subjects. Am J Cardiol 76(17):1233–1238CrossRefPubMedGoogle Scholar
  13. 13.
    O’Neil CE, Keast DR, Fulgoni VL, Nicklas TA (2010) Tree nut consumption improves nutrient intake and diet quality in US adults: an analysis of National Health and Nutrition Examination Survey (NHANES) 1999–2004. Asia Pac J Clin Nutr 19(1):142PubMedGoogle Scholar
  14. 14.
    Hu FB, Stampfer MJ (1999) Nut consumption and risk of coronary heart disease: a review of epidemiologic evidence. Curr Atheroscler Rep 1(3):204–209CrossRefPubMedGoogle Scholar
  15. 15.
    Li S-C, Liu Y-H, Liu J-F, Chang W-H, Chen C-M, Chen C-YO (2011) Almond consumption improved glycemic control and lipid profiles in patients with type 2 diabetes mellitus. Metabolism 60(4):474–479CrossRefPubMedGoogle Scholar
  16. 16.
    Li N, Jia X, Chen C-YO, Blumberg JB, Song Y, Zhang W, Zhang X, Ma G, Chen J (2007) Almond consumption reduces oxidative DNA damage and lipid peroxidation in male smokers. J Nutr 137(12):2717–2722CrossRefPubMedGoogle Scholar
  17. 17.
    Liu J-F, Liu Y-H, Chen C-M, Chang W-H, Chen CO (2012) The effect of almonds on inflammation and oxidative stress in Chinese patients with type 2 diabetes mellitus: a randomized crossover controlled feeding trial. Eur J Nutr 52(3):1–9Google Scholar
  18. 18.
    Tan S, Mattes R (2013) Appetitive, dietary and health effects of almonds consumed with meals or as snacks: a randomized, controlled trial. Eur J Clin Nutr 67(11):1205–1214CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Wien M, Bleich D, Raghuwanshi M, Gould-Forgerite S, Gomes J, Monahan-Couch L, Oda K (2010) Almond consumption and cardiovascular risk factors in adults with prediabetes. J Am Coll Nutr 29(3):189–197CrossRefPubMedGoogle Scholar
  20. 20.
    Berryman CE, Preston AG, Karmally W, Deckelbaum RJ, Kris-Etherton PM (2011) Effects of almond consumption on the reduction of LDL-cholesterol: a discussion of potential mechanisms and future research directions. Nutr Rev 69(4):171–185CrossRefPubMedGoogle Scholar
  21. 21.
    Musa-Veloso K, Paulionis L, Poon T, Lee HY (2016) The effects of almond consumption on fasting blood lipid levels: a systematic review and meta-analysis of randomised controlled trials. J Nutr Sci 5(34):1–15Google Scholar
  22. 22.
    Liu Z, Lee H-J, Garofalo F, Jenkins DJ, El-Sohemy A (2011) Simultaneous measurement of three tocopherols, all-trans-retinol, and eight carotenoids in human plasma by isocratic liquid chromatography. J Chromatogr Sci 49(3):221–227CrossRefGoogle Scholar
  23. 23.
    Volpi N, Tarugi P (1998) Improvement in the high-performance liquid chromatography malondialdehyde level determination in normal human plasma. J Chromatogr B Biomed Sci Appl 713(2):433–437CrossRefPubMedGoogle Scholar
  24. 24.
    Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL (2003) Markers of inflammation and cardiovascular disease application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 107(3):499–511CrossRefPubMedGoogle Scholar
  25. 25.
    Burns AM, Zitt MA, Rowe CC, Langkamp-Henken B, Mai V, Nieves C, Ukhanova M, Christman MC, Dahl WJ (2016) Diet quality improves for parents and children when almonds are incorporated into their daily diet: a randomized, crossover study. Nutr Res 36(1):80–89CrossRefPubMedGoogle Scholar
  26. 26.
    Chen CO, Holbrook M, Duess M-A, Dohadwala MM, Hamburg NM, Asztalos BF, Milbury PE, Blumberg JB, Vita JA (2015) Effect of almond consumption on vascular function in patients with coronary artery disease: a randomized, controlled, cross-over trial. Nutr J 14(1):1CrossRefGoogle Scholar
  27. 27.
    Foster GD, Shantz KL, Vander Veur SS, Oliver TL, Lent MR, Virus A, Szapary PO, Rader DJ, Zemel BS, Gilden-Tsai A (2012) A randomized trial of the effects of an almond-enriched, hypocaloric diet in the treatment of obesity. Am J Clin Nutr 96(2):249–254CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Expert Panel on Detection (2001) Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19):2486–2497CrossRefGoogle Scholar
  29. 29.
    Ministry of Health and Welfare, The Korean Nutrition Society (2015) Dietary Reference Intakes for Koreans 2015. Sejong: Ministry of Health and WelfareGoogle Scholar
  30. 30.
    Fraser GE, Bennett HW, Jaceldo KB, Sabaté J (2002) Effect on body weight of a free 76 kilojoule (320 calorie) daily supplement of almonds for 6 months. J Am Coll Nutr 21(3):275–283CrossRefPubMedGoogle Scholar
  31. 31.
    Cassady BA, Hollis JH, Fulford AD, Considine RV, Mattes RD (2009) Mastication of almonds: effects of lipid bioaccessibility, appetite, and hormone response. Am J Clin Nutr 89(3):794–800CrossRefPubMedGoogle Scholar
  32. 32.
    Hull S, Re R, Chambers L, Echaniz A, Wickham MS (2015) A mid-morning snack of almonds generates satiety and appropriate adjustment of subsequent food intake in healthy women. Eur J Nutr 54(5):803–810CrossRefPubMedGoogle Scholar
  33. 33.
    Jenkins DJ, Kendall CW, Marchie A, Parker TL, Connelly PW, Qian W, Haight JS, Faulkner D, Vidgen E, Lapsley KG (2002) Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein (a), homocysteine, and pulmonary nitric oxide a randomized, controlled, crossover trial. Circulation 106(11):1327–1332CrossRefPubMedGoogle Scholar
  34. 34.
    Novotny JA, Gebauer SK, Baer DJ (2012) Discrepancy between the Atwater factor predicted and empirically measured energy values of almonds in human diets. Am J Clin Nutr 96(2):296–301CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Jaceldo-Siegl K, Sabaté J, Rajaram S, Fraser GE (2004) Long-term almond supplementation without advice on food replacement induces favourable nutrient modifications to the habitual diets of free-living individuals. Brit J Nutr 92(03):533–540CrossRefPubMedGoogle Scholar
  36. 36.
    Jambazian PR, Haddad E, Rajaram S, Tanzman J, Sabaté J (2005) Almonds in the diet simultaneously improve plasma α-tocopherol concentrations and reduce plasma lipids. J Am Diet Assoc 105(3):449–454CrossRefPubMedGoogle Scholar
  37. 37.
    Jaceldo-Siegl K, Sabaté J, Batech M, Fraser G (2011) Influence of body mass index and serum lipids on the cholesterol-lowering effects of almonds in free-living individuals. Nutr Metab Cardiovasc Dis 21:S7–S13CrossRefPubMedGoogle Scholar
  38. 38.
    Spiller GA, Miller A, Olivera K, Reynolds J, Miller B, Morse SJ, Dewell A, Farquhar JW (2003) Effects of plant-based diets high in raw or roasted almonds, or roasted almond butter on serum lipoproteins in humans. J Am Coll Nutr 22(3):195–200CrossRefPubMedGoogle Scholar
  39. 39.
    Spiller GA, Jenkins DA, Bosello O, Gates JE, Cragen LN, Bruce B (1998) Nuts and plasma lipids: an almond-based diet lowers LDL-C while preserving HDL-C. J Am Coll Nutr 17(3):285–290CrossRefPubMedGoogle Scholar
  40. 40.
    Abbey M, Noakes M, Belling GB, Nestel PJ (1994) Partial replacement of saturated fatty acids with almonds or walnuts lowers total plasma cholesterol and low-density-lipoprotein cholesterol. Am J Clin Nutr 59(5):995–999CrossRefPubMedGoogle Scholar
  41. 41.
    Ruisinger JF, Gibson CA, Backes JM, Smith BK, Sullivan DK, Moriarty PM, Kris-Etherton P (2015) Statins and almonds to lower lipoproteins (the STALL Study). J Clinic Lipidol 9(1):58–64CrossRefGoogle Scholar
  42. 42.
    Lee YJ, Nam GE, Seo JA, Yoon T, Seo I, Lee JH, Im D, Bahn K-N, Jeong SA, Kang TS (2014) Nut consumption has favorable effects on lipid profiles of Korean women with metabolic syndrome. Nutr Res 34(9):814–820CrossRefPubMedGoogle Scholar
  43. 43.
    Han JM, Jo AN, Lee SM, Bae HS, Jun DW, Cho YK, Suk KT, Yoon JH, Ahn SB, Cho YJ (2014) Associations between intakes of individual nutrients or whole food groups and non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 29(6):1265–1272CrossRefPubMedGoogle Scholar
  44. 44.
    Chung CE (2007) Dietary intakes and food sources of total sugars from Korean National Health and Nutrition Examination Survey 2001–2002. Korean J Nutr 40(Suppl):9–21Google Scholar
  45. 45.
    Lee HS, Kwon SO, Yon M, Kim D, Lee JY, Nam J, Kwon OS (2014) Dietary total sugar intake of Koreans: based on the Korea National Health and Nutrition Examination Survey (KNHANES), 2008–2011. J Nutr Health 47(4):268–276CrossRefGoogle Scholar
  46. 46.
    US Food Drug Administration (2003) Qualified health claims: letter of enforcement discretion—nuts and coronary heart disease. US Food and Drug Administration, Rockville, pp 1–4Google Scholar
  47. 47.
    Choudhury K, Clark J, Griffiths HR (2014) An almond-enriched diet increases plasma α-tocopherol and improves vascular function but does not affect oxidative stress markers or lipid levels. Free Radic Res 48(5):599–606CrossRefPubMedGoogle Scholar
  48. 48.
    Kim J, Yang Y, Yang Y, Oh S, Hong Y, Lee E, Kwon O (2011) Diet quality scores and oxidative stress in Korean adults. Eur J Clin Nutr 65(12):1271–1278CrossRefPubMedGoogle Scholar
  49. 49.
    Rajaram S, Connell KM, Sabaté J (2010) Effect of almond-enriched high-monounsaturated fat diet on selected markers of inflammation: a randomised, controlled, crossover study. Brit J Nutr 103(06):907–912CrossRefPubMedGoogle Scholar
  50. 50.
    Welsh P, Murray HM, Ford I, Trompet S, de Craen AJ, Jukema JW, Stott DJ, McInnes IB, Packard CJ, Westendorp RG (2011) Circulating interleukin-10 and risk of cardiovascular events a prospective study in the elderly at risk. Arterioscler Thromb Vasc Biol 31(10):2338–2344CrossRefPubMedGoogle Scholar
  51. 51.
    Hwang S-J, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Boerwinkle E (1997) Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96(12):4219–4225CrossRefPubMedGoogle Scholar
  52. 52.
    van Beek L, Lips MA, Visser A, Pijl H, Ioan-Facsinay A, Toes R, Berends FJ, van Dijk KW, Koning F, van Harmelen V (2014) Increased systemic and adipose tissue inflammation differentiates obese women with T2DM from obese women with normal glucose tolerance. Metabolism 63(4):492–501CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Hana Jung
    • 1
  • C.-Y. Oliver Chen
    • 2
  • Jeffrey B. Blumberg
    • 2
  • Ho-Kyung Kwak
    • 1
    Email author
  1. 1.Department of Human EcologyKorea National Open UniversitySeoulRepublic of Korea
  2. 2.Antioxidants Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on AgingTufts UniversityBostonUSA

Personalised recommendations